News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Acrux.
RELATED STOCKHEAD STORIES
Stockhead TV
StockTalk: Drug delivery tech offers patients, investors massive upside
Health & Biotech
Drug delivery technology: How it works, and the ASX companies with plans to capitalise
Health & Biotech
All of 1300 Smiles’ Jobkeeper subsidy has gone on its dividend
Health & Biotech
Dr Boreham’s Crucible: Dimerix not putting all its eggs in one basket
News
ASX Small Cap Lunch Wrap: Who’s keeping it ‘briefs’ today?
News
10 at 10: These ASX stocks are back with a bang this morning
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
The pandemic could be a watershed moment for wellness products
News
Lunchtime ASX small cap wrap: who’s leaping higher today
Health & Biotech
Acrux poked an $8.7bn bear and now it’s fighting back; shares drop 24pc
Health & Biotech
A year after cold shower Acrux rebuild gets underway with first generic drug
Health & Biotech
What’s next for Acrux after end of US Axiron deal
News
Valor flies, ZipTel fails in our weekly ASX small cap wrap
Health & Biotech
What’s next for Acrux after collapse of US deal prompts 30pc share price plunge
Health & Biotech
